Member Info for Dhhlindy

Cavendish in their review suggest a raise of £7m in early 2025 which should see them through to break even in 2027. They indicate a price target of 66p.

Their confidence in the fund raise and target price suggests strength rather than being a problem.

Is there any indication as to timescale for the LO acquisition?

Yes absolutely stunning results with delivery of the four year plan. I can’t believe that these are not at least 80p.

Come on ST wave your wand.

Extract from Cavendish research note:

Outlook. Eden notes that it remains on track to meet 2024 market expectations for revenue, operating profit and the key financial metrics. As in FY23, we anticipate a H2-weighting for revenues in FY24E and maintain our existing forecasts, which anticipate revenue growth of c50% in H2/24 to deliver £5.0m of revenues for the year. We expect the company to close FY24 with cash of £2.8m.

— 2025. We anticipate the following significant updates from Eden Research in 2025: Mevalone sales in California; regulatory submission of the insecticide product in the US and Europe; regulatory approval in France for Mevalone to treat powdery and downy mildew; and full Ecovelex authorisation in the EU

Cavendish in their research note estimate y/e revenue 2024 will be £5mill up from £3.2mill actual in y/e 2023

Cavendish have today released a very positive update. As a long term holder, currently well under water, I do believe things will improve considerably over the next twelve months.

If they miss it by more than a few days I guess Cavendish will be pretty pi***d

In the Sept trading update they said audit would be complete and accounts published by end of Oct Therefore tomorrow. If not tomorrow then this is likely to take a hit.

https://www.reuters.com/business/aerospace-defense/air-finance-summit-tackles-jet-shortages-amid-china-travel-thaw-2023-01-16/?taid=63c5308d878c9f0001f3486d&utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=twitter
This notes the uptick in activity and the need to bring mothballed planes back into service which requires special additional maintenance support. This should all work to GMAAs advantage and help the share price recovery.

With an uptick in activity, and a shortage of planes, might AVAP with its fleet and purchase options be an attractive morsel for one of the industry big boys? Even if not I agree that they should be an attractive long term hold.

I think your comments are spot on TT. As you say Wordsworth is top notch. He is experienced in international and inter government arbitration.

Things are warming up.

Interesting article today in the grauniad re. Neonicotinoid use and the proposal for them to be allowed for emergency use, despite the govt. previously promising that the would be banned. This is an EU wide problem.
Does anyone know whether any of Eden’s products can be an effective alternative to their use.

Either way it’s all useful background emphasising the importance of Eden’s products and market focus.